Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells - PubMed (original) (raw)
. 2001 Nov 29;20(55):7925-34.
doi: 10.1038/sj.onc.1204990.
Affiliations
- PMID: 11753675
- DOI: 10.1038/sj.onc.1204990
Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells
W M Burke et al. Oncogene. 2001.
Abstract
Signal transducers and activators of transcription (STATs) are transcription factors activated in response to cytokines and growth factors. Constitutively active Stat3 has been shown to mediate oncogenic transformation in cultured cells and induce tumor formation in mice. An increasing number of tumor-derived cell lines as well as samples from human cancer have been reported to express constitutively active Stat3 protein. We previously demonstrated that ovarian cancer cell lines express high levels of constitutively active Stat3. In this study, we show that inhibition of the Stat3 signaling pathway using the Janus Kinase-selective inhibitor, AG490, and a dominant negative Stat3 (Stat3beta) significantly suppresses the growth of ovarian and breast cancer cell lines harboring constitutively active Stat3. In the ovarian cancer cell lines, AG490 also diminished the phosphorylation of Stat3, Stat3 DNA binding activity, and the expression of Bcl-x(L). Further, AG490 induced significant apoptosis in ovarian and breast cancer cell lines expressing high levels of constitutively active Stat3 but had a less profound effect on normal cells lacking constitutively active Stat3. AG490 also enhanced apoptosis induced by cisplatin in ovarian cancer cells. These results suggest that inhibition of Stat3 signaling may provide a potential therapeutic approach for treating ovarian and breast cancers.
Similar articles
- Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells.
Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. Real PJ, et al. Oncogene. 2002 Oct 31;21(50):7611-8. doi: 10.1038/sj.onc.1206004. Oncogene. 2002. PMID: 12400004 - p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3.
Lin J, Tang H, Jin X, Jia G, Hsieh JT. Lin J, et al. Oncogene. 2002 May 2;21(19):3082-8. doi: 10.1038/sj.onc.1205426. Oncogene. 2002. PMID: 12082540 - Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
Buettner R, Mora LB, Jove R. Buettner R, et al. Clin Cancer Res. 2002 Apr;8(4):945-54. Clin Cancer Res. 2002. PMID: 11948098 Review. - Signal transducers and activators of transcription: insights into the molecular basis of oral cancer.
Siavash H, Nikitakis NG, Sauk JJ. Siavash H, et al. Crit Rev Oral Biol Med. 2004 Sep 1;15(5):298-307. doi: 10.1177/154411130401500505. Crit Rev Oral Biol Med. 2004. PMID: 15470267 Review.
Cited by
- Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
Gritsina G, Xiao F, O'Brien SW, Gabbasov R, Maglaty MA, Xu RH, Thapa RJ, Zhou Y, Nicolas E, Litwin S, Balachandran S, Sigal LJ, Huszar D, Connolly DC. Gritsina G, et al. Mol Cancer Ther. 2015 Apr;14(4):1035-47. doi: 10.1158/1535-7163.MCT-14-0800. Epub 2015 Feb 2. Mol Cancer Ther. 2015. PMID: 25646015 Free PMC article. - Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity.
Wu CJ, Sundararajan V, Sheu BC, Huang RY, Wei LH. Wu CJ, et al. Cancers (Basel). 2019 Dec 19;12(1):24. doi: 10.3390/cancers12010024. Cancers (Basel). 2019. PMID: 31861720 Free PMC article. Review. - B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.
Liu H, Tekle C, Chen YW, Kristian A, Zhao Y, Zhou M, Liu Z, Ding Y, Wang B, Mælandsmo GM, Nesland JM, Fodstad O, Tan M. Liu H, et al. Mol Cancer Ther. 2011 Jun;10(6):960-71. doi: 10.1158/1535-7163.MCT-11-0072. Epub 2011 Apr 25. Mol Cancer Ther. 2011. PMID: 21518725 Free PMC article. - Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma.
Bard JD, Gelebart P, Anand M, Amin HM, Lai R. Bard JD, et al. Leukemia. 2008 Aug;22(8):1595-603. doi: 10.1038/leu.2008.129. Epub 2008 May 29. Leukemia. 2008. PMID: 18509351 Free PMC article. - Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer.
Aziz MH, Dreckschmidt NE, Verma AK. Aziz MH, et al. Cancer Res. 2008 Nov 1;68(21):9024-32. doi: 10.1158/0008-5472.CAN-08-2494. Cancer Res. 2008. PMID: 18974148 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous